Metallo-beta-lactmase producing Pseudomonas aeruginosa strains are responsible for several nosocomial outbreaks in tertiary care centres across the world. It is well known that poor outcome occurs when patients with serious infections due to MBL producing organisms are treated with antibiotics to which the organism is completely resistant. Therefore, detection of MBL producing Pseudomonas aeruginosa strains is crucial for optimal treatment of critically ill patients and to prevent the spread of resistance. Aim of the present study is to detect Metallo-beta-lactmase (MBL) production in clinical isolates of Pseudomonas aeruginosa by Imipenem-EDTA Double Disc Synergy test. 100 strains of Pseudomonas aeruginosa isolated from pus, sputum, urinary catheter tip, blood and body fluids were screened for Carbapenem resistance by Kirby-Bauer disk diffusion method and results were interpreted as per CLSI guidelines. The isolates showing resistant to Imipenem were further tested for MBL production by Imipenem-EDTA Double Disc Synergy test. Out of 100 Pseudomonas aeruginosa strains 15 were resistant to Imipenem. Out of 15 isolates 10 were MBL producers. Proper antibiotic policy and measures to restrict the indiscriminative use of cephalosporins and carbapenems should be taken to minimize the emergence of Metallo-beta-lactmase producing pathogens. | A study of Metallo-beta-lactamase producing pseudomonas Aeruginosa isolates in a Tertiary care Hospital
